Modeling ongoing SARS-CoV2 vaccination strategies in light of emerging data on immunity and viral evolution

根据免疫和病毒进化的新数据对正在进行的 SARS-CoV2 疫苗接种策略进行建模

基本信息

  • 批准号:
    10398368
  • 负责人:
  • 金额:
    $ 17.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-06-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

SUMMARY While SARS-CoV-2, the pathogen causing COVID-19, continues to spread, the rapid development and deployment of effective vaccines provide a means by which we can reduce its future impact. Initial vaccines have shown to be highly effective, however, the current emergence of new SARS-CoV-2 variants, together with indications that of waning immunity, means that continued repeat vaccinations are likely to be required. Here, we will build upon resources we have already developed from our ongoing project aimed at modeling potential norovirus vaccines and our previous work aimed at modeling the impact of vaccination for SARS-CoV-2 Our team has made contributions and investigated the relative population impacts of SARS-CoV-2 vaccines with different mechanisms of action; characterized patterns of virus evolution that have the potential to impact vaccine efficacy and escape; and, examined initial strategies for vaccine deployment with the aim of relaxing social distancing guidelines. We will leverage these data and modeling tools and build on this work to assess more fully the patterns of immune waning and virus evolution. We will then use these data and results and combine them with our existing SARS-CoV-2 vaccine simulation model to inform the building and the calibration of an extended model. This extended model will account for waning immunity to SARS-CoV-2 and its viral evolution. Our model will inform rapidly emerging scientific questions around continued SARS-CoV-2 vaccination and re-vaccination strategies, including both boosting and vaccine reformulation.
总结 虽然引起COVID-19的病原体SARS-CoV-2继续传播,但快速发展和 部署有效的疫苗提供了一种手段,使我们能够减少其未来的影响。最初的疫苗 然而,目前出现的新的SARS-CoV-2变体,以及 免疫力下降的迹象意味着可能需要继续重复接种疫苗。在这里, 我们将建立在我们已经从我们正在进行的旨在模拟潜力的项目中开发的资源之上, 诺如病毒疫苗和我们以前的工作旨在模拟SARS-CoV-2疫苗接种的影响。 研究小组做出了贡献,并调查了SARS-CoV-2疫苗对人群的相对影响, 不同的作用机制;病毒演变的特征模式,有可能影响 疫苗效力和逃逸;并审查了疫苗部署的初步战略,目的是放松 社交距离准则。我们将利用这些数据和建模工具,并在此基础上评估 更充分地了解免疫衰退和病毒进化的模式。我们将使用这些数据和结果, 联合收割机与我们现有的SARS-CoV-2疫苗模拟模型相结合,为模型的建立和标定提供信息 一个扩展的模型。这个扩展的模型将解释SARS-CoV-2及其病毒引起的免疫力下降 进化我们的模型将为围绕持续的SARS-CoV-2的快速出现的科学问题提供信息 疫苗接种和再接种策略,包括加强和疫苗重新配制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Benjamin A Lopman其他文献

Benjamin A Lopman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Benjamin A Lopman', 18)}}的其他基金

COVID-19 - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings
COVID-19 - 全球混合/资源匮乏环境中传播模型的 COVID-19 疾病参数调查
  • 批准号:
    10367612
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
COVID-19 - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings
COVID-19 - 全球混合/资源匮乏环境中传播模型的 COVID-19 疾病参数调查
  • 批准号:
    10577833
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
COVID Global Mix - Global Mix / Investigation of COVID-19 Disease Parameters for Transmission Models in Low-Resource Settings
COVID Global Mix - 全球混合/资源匮乏环境中传播模型的 COVID-19 疾病参数调查
  • 批准号:
    10863617
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
Comprehensive Profiling of Social Mixing Patterns in Resource Poor Countries
资源匮乏国家社会混合模式的综合分析
  • 批准号:
    10397072
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:
Comprehensive Profiling of Social Mixing Patterns in Resource Poor Countries
资源匮乏国家社会混合模式的综合分析
  • 批准号:
    10610730
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:
Integrating data streams with multi-scale modeling to guide norovirus vaccine decision-making
将数据流与多尺度建模相结合,指导诺如病毒疫苗决策
  • 批准号:
    10160920
  • 财政年份:
    2018
  • 资助金额:
    $ 17.31万
  • 项目类别:
Integrating data streams with multi-scale modeling to guide norovirus vaccine decision-making
将数据流与多尺度建模相结合,指导诺如病毒疫苗决策
  • 批准号:
    10413200
  • 财政年份:
    2018
  • 资助金额:
    $ 17.31万
  • 项目类别:

相似海外基金

mRNA Delivery of a Panel of Single-Domain Antibodies for Combinatorial Deciphering of Therapeutic Targets for Covid-19 Related Cytokine Release Syndrome
一组单域抗体的 mRNA 递送,用于组合破译 Covid-19 相关细胞因子释放综合征的治疗靶点
  • 批准号:
    10383635
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
Design, development, and validation of an end-user assay for low-cost, on-site, and rapid quantification of COVID-19 antigen and antibodies
设计、开发和验证最终用户检测方法,以低成本、现场快速定量 COVID-19 抗原和抗体
  • 批准号:
    570531-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Alliance Grants
Analysis of severe COVID-19 factors -establishment of research basis focusing on anti-type I IFN antibodies-
COVID-19重症因素分析-以抗I型IFN抗体为重点的研究基础的建立-
  • 批准号:
    22K16369
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of COVID-19 antibodies, cell-mediated immunity and telomeres following COVID-19 immunization or natural infection in an immune compromised population: An HIV Cohort Study
在免疫受损人群中进行 COVID-19 免疫或自然感染后评估 COVID-19 抗体、细胞介导的免疫和端粒:一项 HIV 队列研究
  • 批准号:
    448972
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Operating Grants
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
COVID-19 变异补充剂 - 开发候选疫苗和单克隆抗体,以阻断新型冠状病毒 COVID-19 的传播。
  • 批准号:
    443201
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Operating Grants
COVID-19 Variant Supplement - A low-cost, portable, and decentralized microfluidic device for detecting SARS-CoV-2 neutralizing antibodies
COVID-19 变异补充剂 - 一种低成本、便携式、分散式微流体设备,用于检测 SARS-CoV-2 中和抗体
  • 批准号:
    443274
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Operating Grants
Measuring salivary antibodies (Abs) in COVID-19 vaccinated children
测量已接种 COVID-19 疫苗的儿童的唾液抗体 (Abs)
  • 批准号:
    459280
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Operating Grants
Design, development, and validation of an end-user assay for low-cost, on-site, and rapid quantification of COVID-19 antigen and antibodies
设计、开发和验证最终用户检测方法,以低成本、现场快速定量 COVID-19 抗原和抗体
  • 批准号:
    570531-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Alliance Grants
SBIR Phase I: Medical Device to Isolate and Purify Therapeutic Antibodies from Recovered Donors (COVID-19)
SBIR 第一阶段:从康复捐献者中分离和纯化治疗性抗体的医疗设备 (COVID-19)
  • 批准号:
    2036188
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Standard Grant
STTR Phase I: A platform for the rapid discovery of human antibodies as therapeutics for infectious disease (COVID-19)
STTR 第一阶段:快速发现人类抗体作为传染病治疗药物的平台(COVID-19)
  • 批准号:
    2036233
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了